

THE UNIVERSITY OF MANCHESTER
ANIMAL WELFARE AND ETHICAL REVIEW BODY

Wednesday, 28th September 2016

1. Minutes

Confirmed: The minutes of the meeting held on 27th July 2016.

2. Matters arising

2.1 Extracellular Matrix in Development & Disease

Reported: That after a meeting with AWERB representatives, the applicant had edited the NTS and the project was approved.

2.2 Zebrafish: Development, Physiology & Disease Modelling

Reported: That the Home Office had confirmed that they preferred the non-ASPA work to be included in the application, as originally presented. The AWERB1 form had therefore been re-circulated to AWERB members who endorsed a recommendation that the application be approved.

2.3 Immunopathology of Experimental Malaria Infection

Reported: That amendments to the NTS had been completed and the application approved.

2.4 Allegation of work being undertaken outside Home Office licence (minutes of 2 June 2016, actum 9)

Reported: That the individual concerned had left the University and the Home Office had removed his personal licence.

3. Report on licences processed 11.07.16 to 16.09.16

Reported: (a) That the following amendments to project licences had been approved by the executive group:

70/8136	<i>Regulation of the inflammation in wound repair.</i>
70/8181	<i>Development and refinement of small animal imaging.</i>
40/3610	<i>Stress hormones and development of diabetes and obesity</i>
40/3617	<i>Cerebral Ischaemia & the Impact of Co-Morbidity</i>

(b) Amendments to 70/8858, Generation, breeding and maintenance of genetically altered animals:

To produce a PKC α -null mouse (DBA/2J).

To produce a floxed-rhodopsin mouse model using CRISPR/Cas9 KI

To produce enZFHX4 mouse embryos using CRISPR/Cas9 Rosa26 KI

(c) That for Personal Licences there were 5 new licences, 2 amendments, 12 surrendered and 0 renewed.

4. Applications for new Project Licences

4.1 PKC α & Vascular Calcification in Kidney Dysfunction

Considered: A completed AWERB1 form, with written comments by the NVS, NACWO and NTCO.

Interviewed:

Noted:

- (a) That this replaced a previous licence.
- (b) That the methods of measuring calcification needed to be clarified
- (c) That the applicant agreed to report any negative results.
- (d) That the pilot study required 48 mice because there were a number of issues that needed to be addressed at the same time.
- (e) That the following revisions were required:

- Providing a statement about how vascular calcification would be measured.
- Adding an explanation of the post mortem imaging to the NTS

Resolved: To recommend approval, subject to the above revisions.

4.2 Regenerative Medicine Therapy for Renal Injury

Considered: A completed AWERB1 form, with written comments by the NVS, NACWO and NTCO.

Interviewed:

Noted:

- (a) That the project, if successful, had immediate clinical application..
- (b) That the techniques were already tested and running by a collaborator, but AWERB members were still concerned that the model was viable.
- (c) That blood clotting in renal transplants was a risk factor and members sought assurances that this could be avoided with the technics used in these experiments.
- (d) That the following revisions were required:

- Modifying the statement at the top of page 3 of the application to indicate that the risks of anaesthesia will be mitigated rather than be unavoidable.

- Providing assurances from your Glasgow collaborators, publications or peer reviews that the model is a viable one.

Resolved: To recommend approval, subject to the above revisions.

4.3 *Skin Homeostasis and Wound Healing*

Considered: A completed AWERB1 form, with written comments by the NVS, NACWO and NTCO.

Interviewed:

Noted: A commitment in the letter from the project funders, to the publication of the results of the research, including negative results, in open-access, high impact journals and international conferences.

Resolved: To recommend approval.

4.4 *Circadian Mechanisms Underlying Organ Rejection*

Considered: A completed AWERB1 form, with written comments by the NVS, NACWO and NTCO.

Interviewed:

Resolved: To recommend approval.

5. **Visit by Accreditation Board**

The NTCO reported that the Accreditation Board had visited the University on 19th September and the meeting went well. A formal report would be received in November.